A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia.
A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit (ICU) reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia (AML).
A disease with dismal outcomes, about 75% of patients diagnosed with AML do not survive for more than 5 years. With the objective of examining the risk factors, mortality, length of stay (LOS), and cost associated with admission to the ICU for patients with AML, scientists at Fred Hutch extracted data from the University HealthSystem Consortium database on adult patients diagnosed with AML and who were hospitalized between January 1, 2004, and December 21, 2012. The primary outcomes being evaluated were admission to the ICU and inpatient mortality among patients who needed ICU care. Secondary outcomes included LOS in ICU, total LOS, and cost.
During the study period, a little more than 25% (11,277) of patients diagnosed with AML were admitted to the ICU. Risk factors for admissions included:
In-hospital mortality was significantly greater in patients who needed ICU care (4857 of 11,277 [43.1%] vs 2959 of 31,972 [9.3%]). The authors identified the following risk factors for death in the ICU-admitted cohort:
Simultaneous with the increased ICU admission was the increased cost of care—patients who needed the intensive care treatment incurred nearly double the cost of those who were not in the ICU ($83,354 versus $41,973, respectively). Presence of comorbidities further accentuated treatment costs, from $50,543 for no comorbidities, all the way to $124,820 in patients with at least 5 comorbidities.
The authors conclude that while comorbidities increase the risk of mortality and cost of care in patients with AML, appropriate interventions by identifying patients at high risk for ICU use could reduce fatalities.
Reference
Halpen AB, Culakova E, Walter RB, Lyman GH. Association of risk factors, mortality, and care costs of adults with Acute Myeloid Leukemia with admission to the intensive care unit [published online November 10, 2016]. JAMA Oncol. doi: 10.1001/jamaoncol.2016.4858.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More